Guidelines: Difference between revisions

No edit summary
Line 43: Line 43:


* [[AUA: Management of LUTS Attributed to BPH (2021)|Management of LUTS Attributed to BPH (2021)]]
* [[AUA: Management of LUTS Attributed to BPH (2021)|Management of LUTS Attributed to BPH (2021)]]
*[[AUA: Overactive Bladder (2019)|OAB (2019)]]
*[[AUA: Overactive Bladder (2019)|Overactive Bladder (2019)]]
*[[AUA & CUA Mesh Position Statement (2019)|AUA/CUA Mesh Position Statement (2019)]]
*[[AUA & CUA Mesh Position Statement (2019)|AUA/CUA Mesh Position Statement (2019)]]
* [[AUA: Incontinence after Prostate Therapy (2019)|Incontinence after Prostate Therapy (2019)]]
* [[AUA: Incontinence after Prostate Therapy (2019)|Incontinence after Prostate Therapy (2019)]]